| pubmed-article:20126544 | pubmed:abstractText | Aberrant beta-catenin signaling plays a key role in several cancer types, notably colon, liver and breast cancer. However approaches to modulate beta-catenin activity for therapeutic purposes have proven elusive to date. | lld:pubmed |
